Prescription Drugs Market Report 2026

Prescription Drugs Market Overview

• Prescription Drugs market size has reached to $1430.3 billion in 2025 • Expected to grow to $2368.39 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Rising Drug Production and Its Influence on Prescription Drug Market Growth • Market Trend: Expanding Access To GLP-1 Receptor Agonist Therapies For Type 2 Diabetes Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Prescription Drugs Market?

Prescription drugs refer to medications that are legally available only with a valid prescription from a licensed healthcare provider, used to treat, manage, or prevent various medical conditions. It is used to diagnose, treat, manage, or prevent medical conditions under the supervision of a healthcare professional, ensuring the appropriate use and minimizing the risk of misuse or adverse effects. The main types of prescription drugs include branded and generic. Branded prescription drugs are medications marketed under a proprietary, trademarked name given by the pharmaceutical company that develops and patents the drug. The routes of administration include oral, topical, parenteral, and others for therapy areas that include oncology, immunology, ophthalmology, respiratory, dermatology, gastroenterology, urology, gynecology, endocrinology, and others. The end users include hospitals, specialty clinics, homecare, and others.

What Is The Prescription Drugs Market Growth Forecast?

The prescription drugs market size is expected to see rapid growth in the next few years. It will grow to $2368.39 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for cost-effective generics, rising adoption of biosimilars, expansion of digital prescription platforms, growing focus on personalized drug therapies, increasing regulatory harmonization across markets. Major trends in the forecast period include increasing adoption of specialty prescription drugs, rising demand for generic drug alternatives, growing focus on chronic disease management, expansion of biologic and biosimilar therapies, enhanced regulatory oversight of drug safety.

Global Prescription Drugs Market Segmentation

1) By Type: Branded, Generics 2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration 3) By Therapy Area: Oncology, Immunology, Ophthalmology, Respiratory, Dermatology, Gastroenterology, Urology, Gynecology, Endocrinology, Other Therapy Areas 4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Branded: Innovative Drugs, Patented Drugs, Blockbuster Drugs, Over-the-Counter (OTC) Prescription Drugs, Biosimilars, Specialty Drugs, Orphan Drugs, Combination Drugs 2) By Generics: Small Molecule Generics, Generic Biologics, Over-the-Counter (OTC) Generics, Authorized Generics, Generic Combination Drugs, High-Volume Generics, Generic Versions Of Blockbuster Drugs

What Is The Driver Of The Prescription Drugs Market?

The increasing drug production is expected to propel the growth of the prescription drug market going forward. Drug production encompasses the organized process of creating pharmaceutical products, including their formulation, testing, and packaging, to guarantee quality, safety, and effectiveness. Increasing drug production is crucial to meet the growing global demand for medications, address public health challenges, and ensure the timely availability of treatments for diverse medical conditions. The increasing drug production can enhance the availability, affordability, and innovation in the prescription drug market, ultimately benefiting patients and the healthcare system by improving access to essential medications and supporting better health outcomes. For instance, in October 2025, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based organization representing the pharmaceutical sector, the European pharmaceutical industry experienced substantial production, rising from $438 billion (€405,701 million) in 2023 to $475 billion (€440,000 million) in 2024. Therefore, increasing drug production will drive the development of the prescription drug industry.

Key Players In The Global Prescription Drugs Market

Major companies operating in the prescription drugs market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited

Global Prescription Drugs Market Trends and Insights

Major companies operating in the prescription drug market are developing Victoza (liraglutide) alternatives or similar GLP-1 receptor agonist therapies to provide enhanced options for managing type 2 diabetes. Victoza is a brand-name prescription medication that contains the active ingredient liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used primarily to manage type 2 diabetes in adults and children aged 10 years and older. For instance, in June 2024, Teva Announces, an Israel-based company, launched an authorized generic of Victoza (liraglutide injection 1.8 mg), offering a more affordable alternative while maintaining the same formulation, efficacy, and quality as the original branded product. This launch aims to improve access to essential diabetes treatments for patients, providing cost-effective options for managing type 2 diabetes and reducing cardiovascular risks associated with the condition.

What Are Latest Mergers And Acquisitions In The Prescription Drugs Market?

In December 2023, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. Through this acquisition, Bristol Myers Squibb aims to strengthen its neuroscience portfolio by integrating Karuna’s novel cholinergic-based therapies, including KarXT, and expanding its pipeline of treatments for schizophrenia and Alzheimer’s disease psychosis. Karuna Therapeutics is a US-based biopharma company that develops prescription drugs for neuroscience disorders.

Regional Insights

North America was the largest region in the prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prescription Drugs Market?

The prescription drugs market consists of sales of bronchodilators, corticosteroids, combination inhalers, antibiotics, mucolytics, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prescription Drugs Market Report 2026?

The prescription drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prescription drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.